TGF-β inhibitors not only normalize tumor stroma by reducing collagen I content but also improve the ability of other anticancer drugs to penetrate tumors more effectively [131], resulting in a significant reduction in tumor growth and metastasis. The gene discussed is TGFB1; the disease is neoplasm.